Michael D. Rainey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael D. Rainey has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Corrado Santocanale
Centre for Chromosome Biology, School of Biological and Chemical Sciences, University of Galway, Galway, Ireland
17 shared publications - David Af Gillespie
The Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61 1BD, UK
5 shared publications - Anja Göder
Institute of Toxicology, University Medical Center Mainz, Mainz 55131, Germany
3 shared publications - Colm J. Ryan
Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
3 shared publications - David C. A. Gaboriau
Facility for Imaging by Light Microscopy, National Heart and Lung Institute, Imperial College London, London, UK
3 shared publications George Zachos
Beatson Institute for Cancer Research
3 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in The EMBO Journal
- p. 1-40
CDC7 and CDK8 kinases cooperate to support DNA replication origin firing in human cells
The coordinated activation of DNA replication origins is important for efficient DNA synthesis and genome stability. S-phase cyclin-dependent kinases (CDKs), together with CDC7 kinase, are essential for origin activation by converting the pre-replicative complex into a fully active helicase. Here, in order to identify genes that tune DNA replication, we performed a chemogenetic genome-wide CRISPR-KO screen in cells challenged with the CDC7 inhibitor XL413. By developing a methodology based on genetic co-essentiality to functionally cluster the hits, we uncover the transcriptional CDK8/CCNC kinase in a cluster with replication initiation factors. Depletion of CDK8 further reduces the rate of DNA synthesis imposed by CDC7 inhibitors. DNA fibre experiments further support that CDK8 and CDC7 cooperate in origin activation. Suppression of DNA synthesis by CDK8 inhibition requires the binding of CDK8/CCNC to the MDM2 Binding Protein (MTBP), and we show that CDC7 and CDK8 associate with the MCM complex and individually contribute to the phosphorylation of the replicative helicase. In conclusion, this work adds CDK8 to the list of kinases directly involved in origin activation in human cells.
- 2 November 2026
- Published by Springer Nature in The EMBO Journal
- p. 1-40
Open AccessCDC7 and CDK8 kinases cooperate to support DNA replication origin firing in human cells
The coordinated activation of DNA replication origins is important for efficient DNA synthesis and genome stability. S-phase cyclin-dependent kinases (CDKs), together with CDC7 kinase, are essential for origin activation by converting the pre-replicative complex into a fully active helicase. Here, in order to identify genes that tune DNA replication, we performed a chemogenetic genome-wide CRISPR-KO screen in cells challenged with the CDC7 inhibitor XL413. By developing a methodology based on genetic co-essentiality to functionally cluster the hits, we uncover the transcriptional CDK8/CCNC kinase in a cluster with replication initiation factors. Depletion of CDK8 further reduces the rate of DNA synthesis imposed by CDC7 inhibitors. DNA fibre experiments further support that CDK8 and CDC7 cooperate in origin activation. Suppression of DNA synthesis by CDK8 inhibition requires the binding of CDK8/CCNC to the MDM2 Binding Protein (MTBP), and we show that CDC7 and CDK8 associate with the MCM complex and individually contribute to the phosphorylation of the replicative helicase. In conclusion, this work adds CDK8 to the list of kinases directly involved in origin activation in human cells.
- Open Access
A survey of multi-targeting and off-targeting sgRNAs across five genome-wide CRISPR-Cas9 knockout sgRNA libraries with GuideRefine
Pooled genome-wide CRISPR-Cas9 knockout (CRISPR-KO) screening is a powerful approach for discovering new biology and identifying genetic vulnerabilities in cancers. This approach uses the Cas9 nuclease in combination with sgRNA libraries, typically consisting of 4-8 sgRNAs to induce mutations in each target gene. A critical assumption is that the effect of each sgRNA is solely due to Cas9 editing of the target gene. However, libraries can contain sgRNAs that direct Cas9 to multiple locations, thus potentially introducing bias into gene hit lists and leading to flawed biological hypotheses. Here we have developed GuideRefine, a pipeline to detect multi-targeting and off-targeting sgRNAs. GuideRefine outputs a virtual refined sub-library containing only on-target sgRNAs. Using GuideRefine with T2T-CHM13 as the reference genome, we surveyed the Brunello, TKOv3, Yusa, Avana, and Jacquere libraries, finding that ~7.5% to ~16% of sgRNAs are potentially problematic. We confirmed that multi-targeting sgRNAs disproportionately impair cell fitness and that sgRNAs aligning to more than one location with a single mismatch can also reduce fitness, although to a lesser extent. After flagging problematic sgRNAs and creating virtual ″on-target only″ sub-libraries, ~10% to ~16% of genes lose critical representation (< 3 sgRNAs per gene). Intriguingly, a set of 467 genes, characterised by short CDS length and lower PAM site density, have fewer than three sgRNAs in all sub-libraries, suggesting they cannot be well-targeted using current libraries. We anticipate that GuideRefine, together with caution in assessing the effects of problematic sgRNAs, will help prioritise biologically relevant hits.
Open AccessA survey of multi-targeting and off-targeting sgRNAs across five genome-wide CRISPR-Cas9 knockout sgRNA libraries with GuideRefine
Pooled genome-wide CRISPR-Cas9 knockout (CRISPR-KO) screening is a powerful approach for discovering new biology and identifying genetic vulnerabilities in cancers. This approach uses the Cas9 nuclease in combination with sgRNA libraries, typically consisting of 4-8 sgRNAs to induce mutations in each target gene. A critical assumption is that the effect of each sgRNA is solely due to Cas9 editing of the target gene. However, libraries can contain sgRNAs that direct Cas9 to multiple locations, thus potentially introducing bias into gene hit lists and leading to flawed biological hypotheses. Here we have developed GuideRefine, a pipeline to detect multi-targeting and off-targeting sgRNAs. GuideRefine outputs a virtual refined sub-library containing only on-target sgRNAs. Using GuideRefine with T2T-CHM13 as the reference genome, we surveyed the Brunello, TKOv3, Yusa, Avana, and Jacquere libraries, finding that ~7.5% to ~16% of sgRNAs are potentially problematic. We confirmed that multi-targeting sgRNAs disproportionately impair cell fitness and that sgRNAs aligning to more than one location with a single mismatch can also reduce fitness, although to a lesser extent. After flagging problematic sgRNAs and creating virtual ″on-target only″ sub-libraries, ~10% to ~16% of genes lose critical representation (< 3 sgRNAs per gene). Intriguingly, a set of 467 genes, characterised by short CDS length and lower PAM site density, have fewer than three sgRNAs in all sub-libraries, suggesting they cannot be well-targeted using current libraries. We anticipate that GuideRefine, together with caution in assessing the effects of problematic sgRNAs, will help prioritise biologically relevant hits.
- Open Access
CDC7 and CDK8 kinases cooperate to support DNA replication origin firing in human cells
The coordinated activation of DNA replication origins is important for efficient DNA synthesis and genome stability. S-phase cyclin dependent kinases (CDKs) together with CDC7 kinase, are essential to origin activation by converting the pre-replicative complex into a fully active helicase. To identify genes that tune DNA replication, we have performed a chemo-genetic genome-wide CRISPR-KO screen with cells challenged with the CDC7 inhibitor XL413. By developing a methodology based on genetic coessentiality to functionally cluster the hits, we uncover the transcriptional CDK8/CCNC kinase in a cluster with replication initiation factors. We find that CDK8 depletion further reduces the rate of DNA synthesis imposed by CDC7 inhibitors. DNA fibre experiments provide compelling evidence that CDK8 and CDC7 cooperate in origin activation. Suppression of DNA synthesis by CDK8 inhibition requires the binding of CDK8/CCNC to the MDM2 Binding Protein (MTBP) and we show that CDC7 and CDK8 individually contribute to the phosphorylation of MCM4 subunit of the replicative helicase. Thus, this work identifies CDK8 as the third protein kinase directly involved in origin activation in human cells.
Open AccessCDC7 and CDK8 kinases cooperate to support DNA replication origin firing in human cells
The coordinated activation of DNA replication origins is important for efficient DNA synthesis and genome stability. S-phase cyclin dependent kinases (CDKs) together with CDC7 kinase, are essential to origin activation by converting the pre-replicative complex into a fully active helicase. To identify genes that tune DNA replication, we have performed a chemo-genetic genome-wide CRISPR-KO screen with cells challenged with the CDC7 inhibitor XL413. By developing a methodology based on genetic coessentiality to functionally cluster the hits, we uncover the transcriptional CDK8/CCNC kinase in a cluster with replication initiation factors. We find that CDK8 depletion further reduces the rate of DNA synthesis imposed by CDC7 inhibitors. DNA fibre experiments provide compelling evidence that CDK8 and CDC7 cooperate in origin activation. Suppression of DNA synthesis by CDK8 inhibition requires the binding of CDK8/CCNC to the MDM2 Binding Protein (MTBP) and we show that CDC7 and CDK8 individually contribute to the phosphorylation of MCM4 subunit of the replicative helicase. Thus, this work identifies CDK8 as the third protein kinase directly involved in origin activation in human cells.
- Open Access
- 12 June 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 223 (8)
DBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks
CDC7 kinase is crucial for DNA replication initiation and is involved in fork processing and replication stress response. Human CDC7 requires the binding of either DBF4 or DRF1 for its activity. However, it is unclear whether the two regulatory subunits target CDC7 to a specific set of substrates, thus having different biological functions, or if they act redundantly. Using genome editing technology, we generated isogenic cell lines deficient in either DBF4 or DRF1: these cells are viable but present signs of genomic instability, indicating that both can independently support CDC7 for bulk DNA replication. Nonetheless, DBF4-deficient cells show altered replication efficiency, partial deficiency in MCM helicase phosphorylation, and alterations in the replication timing of discrete genomic regions. Notably, we find that CDC7 function at replication forks is entirely dependent on DBF4 and not on DRF1. Thus, DBF4 is the primary regulator of CDC7 activity, mediating most of its functions in unperturbed DNA replication and upon replication interference.
- 12 June 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 223 (8)
Open AccessDBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks
CDC7 kinase is crucial for DNA replication initiation and is involved in fork processing and replication stress response. Human CDC7 requires the binding of either DBF4 or DRF1 for its activity. However, it is unclear whether the two regulatory subunits target CDC7 to a specific set of substrates, thus having different biological functions, or if they act redundantly. Using genome editing technology, we generated isogenic cell lines deficient in either DBF4 or DRF1: these cells are viable but present signs of genomic instability, indicating that both can independently support CDC7 for bulk DNA replication. Nonetheless, DBF4-deficient cells show altered replication efficiency, partial deficiency in MCM helicase phosphorylation, and alterations in the replication timing of discrete genomic regions. Notably, we find that CDC7 function at replication forks is entirely dependent on DBF4 and not on DRF1. Thus, DBF4 is the primary regulator of CDC7 activity, mediating most of its functions in unperturbed DNA replication and upon replication interference.
- Open Access
DBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks
Summary: In eukaryotes, CDC7 kinase is crucial for DNA replication initiation and has been involved in fork processing and replication stress response. Human CDC7 requires the binding of either one of two regulatory subunits, DBF4 and DRF1, for its activity. However, it is unclear whether the two regulatory subunits target CDC7 to a specific set of substrates, thus having different biological functions, or if they act redundantly. Using genome editing technology, we generated an isogenic set of cell lines deficient in either one of the two CDC7-activating subunits: these cells are viable but present signs of genomic instability, indicating that both DBF4 and DRF1 can independently support CDC7 for bulk DNA replication. Nonetheless, DBF4-deficient cells show altered replication efficiency, including partial deficiency in MCM helicase phosphorylation and alterations in the replication timing of discrete genomic regions. Notably, we find that CDC7 function at replication forks is entirely dependent on DBF4 and not DRF1. Thus, DBF4 is the primary regulator of CDC7 activity, likely mediating most of its functions in unperturbed DNA replication and during replication fork processing upon replication interference.
Open AccessDBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks
Summary: In eukaryotes, CDC7 kinase is crucial for DNA replication initiation and has been involved in fork processing and replication stress response. Human CDC7 requires the binding of either one of two regulatory subunits, DBF4 and DRF1, for its activity. However, it is unclear whether the two regulatory subunits target CDC7 to a specific set of substrates, thus having different biological functions, or if they act redundantly. Using genome editing technology, we generated an isogenic set of cell lines deficient in either one of the two CDC7-activating subunits: these cells are viable but present signs of genomic instability, indicating that both DBF4 and DRF1 can independently support CDC7 for bulk DNA replication. Nonetheless, DBF4-deficient cells show altered replication efficiency, including partial deficiency in MCM helicase phosphorylation and alterations in the replication timing of discrete genomic regions. Notably, we find that CDC7 function at replication forks is entirely dependent on DBF4 and not DRF1. Thus, DBF4 is the primary regulator of CDC7 activity, likely mediating most of its functions in unperturbed DNA replication and during replication fork processing upon replication interference.
- Open Access
- 1 September 2020
- Published by Elsevier in Cell Reports
- Vol. 32 (9) , 108096
ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition
- 1 September 2020
- Published by Elsevier in Cell Reports
- Vol. 32 (9) , 108096
Open AccessATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition
- Open Access
- 4 June 2020
- Published by Springer Nature in EMBO Reports
- Vol. 21 (8) , e48920
CDC7 kinase promotes MRE11 fork processing, modulating fork speed and chromosomal breakage
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 4 June 2020
- Published by Springer Nature in EMBO Reports
- Vol. 21 (8) , e48920
Open AccessCDC7 kinase promotes MRE11 fork processing, modulating fork speed and chromosomal breakage
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 7 June 2017
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (7) , 1893-1902
DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors
The CDC7 kinase, by phosphorylating the MCM DNA helicase, is a key switch for DNA replication initiation. ATP competitive CDC7 inhibitors are being developed as potential anticancer agents; however how human cells respond to the selective pharmacological inhibition of this kinase is controversial and not understood. Here we have characterized the mode of action of the two widely used CDC7 inhibitors, PHA-767491 and XL-413, which have become important tool compounds to explore the kinase’s cellular functions. We have used a chemical genetics approach to further characterize pharmacological CDC7 inhibition and CRISPR/CAS9 technology to assess the requirement for kinase activity for cell proliferation. We show that, in human breast cells, CDC7 is essential and that CDC7 kinase activity is formally required for proliferation. However, full and sustained inhibition of the kinase, which is required to block the cell-cycle progression with ATP competitor compounds, is problematic to achieve. We establish that MCM2 phosphorylation is highly sensitive to CDC7 inhibition and, as a biomarker, it lacks in dynamic range since it is easily lost at concentrations of inhibitors that only mildly affect DNA synthesis. Furthermore, we find that the cellular effects of selective CDC7 inhibitors can be altered by the concomitant inhibition of cell-cycle and transcriptional CDKs. This work shows that DNA replication and cell proliferation can occur with reduced CDC7 activity for at least 5 days and that the bulk of DNA synthesis is not tightly coupled to MCM2 phosphorylation and provides guidance for the development of next generation CDC7 inhibitors.
- 7 June 2017
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (7) , 1893-1902
DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors
The CDC7 kinase, by phosphorylating the MCM DNA helicase, is a key switch for DNA replication initiation. ATP competitive CDC7 inhibitors are being developed as potential anticancer agents; however how human cells respond to the selective pharmacological inhibition of this kinase is controversial and not understood. Here we have characterized the mode of action of the two widely used CDC7 inhibitors, PHA-767491 and XL-413, which have become important tool compounds to explore the kinase’s cellular functions. We have used a chemical genetics approach to further characterize pharmacological CDC7 inhibition and CRISPR/CAS9 technology to assess the requirement for kinase activity for cell proliferation. We show that, in human breast cells, CDC7 is essential and that CDC7 kinase activity is formally required for proliferation. However, full and sustained inhibition of the kinase, which is required to block the cell-cycle progression with ATP competitor compounds, is problematic to achieve. We establish that MCM2 phosphorylation is highly sensitive to CDC7 inhibition and, as a biomarker, it lacks in dynamic range since it is easily lost at concentrations of inhibitors that only mildly affect DNA synthesis. Furthermore, we find that the cellular effects of selective CDC7 inhibitors can be altered by the concomitant inhibition of cell-cycle and transcriptional CDKs. This work shows that DNA replication and cell proliferation can occur with reduced CDC7 activity for at least 5 days and that the bulk of DNA synthesis is not tightly coupled to MCM2 phosphorylation and provides guidance for the development of next generation CDC7 inhibitors.
- Open Access
- 12 July 2016
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 44 (18) , 8786-8798
DDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach
In eukaryotic cells the CDC7/DBF4 kinase, also known as DBF4-dependent kinase (DDK), is required for the firing of DNA replication origins. CDC7 is also involved in replication stress responses and its depletion sensitises cells to drugs that affect fork progression, including Topoisomerase 2 poisons. Although CDC7 is an important regulator of cell division, relatively few substrates and bona-fide CDC7 phosphorylation sites have been identified to date in human cells. In this study, we have generated an active recombinant CDC7/DBF4 kinase that can utilize bulky ATP analogues. By performing in vitro kinase assays using benzyl-thio-ATP, we have identified TOP2A as a primary CDC7 substrate in nuclear extracts, and serine 1213 and serine 1525 as in vitro phosphorylation sites. We show that CDC7/DBF4 and TOP2A interact in cells, that this interaction mainly occurs early in S-phase, and that it is compromised after treatment with CDC7 inhibitors. We further provide evidence that human DBF4 localises at centromeres, to which TOP2A is progressively recruited during S-phase. Importantly, we found that CDC7/DBF4 down-regulation, as well S1213A/S1525A TOP2A mutations can advance the timing of centromeric TOP2A recruitment in S-phase. Our results indicate that TOP2A is a novel DDK target and have important implications for centromere biology.
- 12 July 2016
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 44 (18) , 8786-8798
Open AccessDDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach
In eukaryotic cells the CDC7/DBF4 kinase, also known as DBF4-dependent kinase (DDK), is required for the firing of DNA replication origins. CDC7 is also involved in replication stress responses and its depletion sensitises cells to drugs that affect fork progression, including Topoisomerase 2 poisons. Although CDC7 is an important regulator of cell division, relatively few substrates and bona-fide CDC7 phosphorylation sites have been identified to date in human cells. In this study, we have generated an active recombinant CDC7/DBF4 kinase that can utilize bulky ATP analogues. By performing in vitro kinase assays using benzyl-thio-ATP, we have identified TOP2A as a primary CDC7 substrate in nuclear extracts, and serine 1213 and serine 1525 as in vitro phosphorylation sites. We show that CDC7/DBF4 and TOP2A interact in cells, that this interaction mainly occurs early in S-phase, and that it is compromised after treatment with CDC7 inhibitors. We further provide evidence that human DBF4 localises at centromeres, to which TOP2A is progressively recruited during S-phase. Importantly, we found that CDC7/DBF4 down-regulation, as well S1213A/S1525A TOP2A mutations can advance the timing of centromeric TOP2A recruitment in S-phase. Our results indicate that TOP2A is a novel DDK target and have important implications for centromere biology.
- Open Access
- 14 April 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8) , 2384-2393
The Deubiquitinase USP9X Maintains DNA Replication Fork Stability and DNA Damage Checkpoint Responses by Regulating CLASPIN during S-Phase
Coordination of the multiple processes underlying DNA replication is key for maintaining genome stability and preventing tumorigenesis. CLASPIN, a critical player in replication fork stabilization and checkpoint responses, must be tightly regulated during the cell cycle to prevent the accumulation of DNA damage. In this study, we used a quantitative proteomics approach and identified USP9X as a novel CLASPIN-interacting protein. USP9X is a deubiquitinase involved in multiple signaling and survival pathways whose tumor suppressor or oncogenic activity is highly context dependent. We found that USP9X regulated the expression and stability of CLASPIN in an S-phase–specific manner. USP9X depletion profoundly impairs the progression of DNA replication forks, causing unscheduled termination events with a frequency similar to CLASPIN depletion, resulting in excessive endogenous DNA damage. Importantly, restoration of CLASPIN expression in USP9X-depleted cells partially suppressed the accumulation of DNA damage. Furthermore, USP9X depletion compromised CHK1 activation in response to hydroxyurea and UV, thus promoting hypersensitivity to drug-induced replication stress. Taken together, our results reveal a novel role for USP9X in the maintenance of genomic stability during DNA replication and provide potential mechanistic insights into its tumor suppressor role in certain malignancies. Cancer Res; 76(8); 2384–93. ©2016 AACR.
- 14 April 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (8) , 2384-2393
Open AccessThe Deubiquitinase USP9X Maintains DNA Replication Fork Stability and DNA Damage Checkpoint Responses by Regulating CLASPIN during S-Phase
Coordination of the multiple processes underlying DNA replication is key for maintaining genome stability and preventing tumorigenesis. CLASPIN, a critical player in replication fork stabilization and checkpoint responses, must be tightly regulated during the cell cycle to prevent the accumulation of DNA damage. In this study, we used a quantitative proteomics approach and identified USP9X as a novel CLASPIN-interacting protein. USP9X is a deubiquitinase involved in multiple signaling and survival pathways whose tumor suppressor or oncogenic activity is highly context dependent. We found that USP9X regulated the expression and stability of CLASPIN in an S-phase–specific manner. USP9X depletion profoundly impairs the progression of DNA replication forks, causing unscheduled termination events with a frequency similar to CLASPIN depletion, resulting in excessive endogenous DNA damage. Importantly, restoration of CLASPIN expression in USP9X-depleted cells partially suppressed the accumulation of DNA damage. Furthermore, USP9X depletion compromised CHK1 activation in response to hydroxyurea and UV, thus promoting hypersensitivity to drug-induced replication stress. Taken together, our results reveal a novel role for USP9X in the maintenance of genomic stability during DNA replication and provide potential mechanistic insights into its tumor suppressor role in certain malignancies. Cancer Res; 76(8); 2384–93. ©2016 AACR.